The FDA is getting better at detecting misapplied practices in clinical trial studies with the help of artificial intelligence, agency Commissioner Robert Califf said Wednesday.
“You apply AI to an application, you find out when people are cheating,” he said. “And if you’ve cheated in the past, watch out because it’s going to be easy to apply AI to the applications we already have to catch in the future.”
“This is an arms race, in a way, because we’re now seeing applications that are generated with AI,” Califf said. “And so we got to stay a step ahead so that ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.